In many cases, heparanase levels correlate with increased tumor metastasis, vascular density, and shorter postoperative survival of cancer patients (14, 16, 18, 20), thus providing strong clinical support for the pro-tumorigenic function of the enzyme and encouraging the development of heparanase inhibitors as anti-cancer drugs (21, 22). This evidence concerns the gene HPSE and cancer.